Amyloidosis News - 2022

Study provides insights into sex-related differences in wild-type transthyretin amyloid cardiomyopathy, underscoring the need for improved care of female patients. Read More ›

Retrospective study finds unfavorable outcomes associated with the Val122Ile TTR variant in black individuals who develop heart failure. Read More ›

Clinical presentation, diagnosis, treatment, and prognosis of renal amyloidosis are codified in a recent review. Read More ›

Distinguishing features can help rule out mimics of transthyretin amyloidosis. Read More ›

Study provides patient perspectives on the debilitating nature of amyloidosis and reveals a delay from symptom onset to diagnosis of >2 years. Read More ›

Optimal care of patients with amyloidosis requires consideration of gastrointestinal burden and nutritional status, necessitating a multidisciplinary approach with gastroenterology involvement. Read More ›

Treatment with tafamidis in patients with transthyretin amyloid cardiomyopathy resulted in delayed structural and functional cardiac changes. Read More ›

Results from a recent study showed a high prevalence of cerebral ischemic events in Afro-Caribbean patients with transthyretin-mediated cardiac amyloidosis and shed light on risk factors for ischemic events in amyloidosis. Read More ›

Researchers investigate microvascular function in patients with cardiac amyloidosis using a new, validated method: dynamic retinal vessel analysis. Read More ›

The first study to examine healthcare resource utilization of patients with transthyretin-mediated cardiac amyloidosis versus patients with heart failure reveals consistent use differential. Read More ›

Page 1 of 4

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.